Do you want to read an article? Please log in or register.
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
Lymphoma
Related content
Leukemia
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
J Clin Oncol
Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM
doi: 10.1200/JCO-25-00166
Leukemia
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation
Leuk Lymphoma
Claiborne JP, Tsai HL, Ghiaur G, Smith BD, Gojo I, DeZern AE, Ambinder AJ, Jain T, Prince GT, Gondek LP, Karantanos T, Dalton WB, Levis MJ, Webster JA
doi: 10.1080/10428194.2026.2628206
Lung, Respiratory and Thoracic Cancer
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
J Thorac Oncol
Brunetti L, Colella G, Di Fazio GR, La Cava G, Santo V, Pecci F, Rotow J, Bauman JR, Nassar AH, Adib E, Naqash AR, Tagliamento M, Ferrara R, Citarella F, Russano M, Ricciuti B, Faivre-Finn C, Hendriks LEL, Passaro A, Vincenzi B, Acker F, Derosa L, Planchard D, Aerts HJWL, Novello S, Passiglia F, Greco C, Ramella S, Cortellini A
doi: 10.1016/j.jtho.2026.103735
Lymphoma
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
J Clin Oncol
Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M, ECHO investigators
doi: 10.1200/JCO-25-00690
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
RECOMMENDED
Head and Neck Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
Lymphoma
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies
Am J Hematol
Atallah-Yunes SA, Nze CC, King RL, Rees MJ, Alderuccio JP, Watkins M, Kahl BS, Easwar N, Yamshon S, Ravindra A, Farooq U, Rosenthal AC, Munoz JL, Rojas-Neira EM, Ayers AA, Moustafa MA, Habermann TM, Witzig TE, Ansell SM, Nowakowski GS, Koff JL, Flowers CR, Wang Y
doi: 10.1002/ajh.70058
Breast Cancer
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Eur J Cancer
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM
doi: 10.1016/j.ejca.2025.116051
Leukemia
Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis
Leuk Lymphoma
Majrashi A, Shantsila A, Gue YX, Williams S, Lip GYH, Pettitt AR
doi: 10.1080/10428194.2026.2653123